I70.9 I25.0
Conditions
Interventions
Group 1: A biobank will be established. Blood and urine will be collected at the time of hospitalization and before any interventional investigations are taken. A part of the blood and urine is examin
Sponsors
Medical University Brandenburg
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients with cardiovascular risk factors, suspicion of cardiovascular disease or known cardiovascular disease
Exclusion criteria
Exclusion criteria: Acute infectious disease, active cancer, inability to give written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Dysfunctional HDL is a risk factor for arteriosclerosis and correlates with IMT (intima-media-thickness) and with FMD independent of HDL-C (primary endpoint). - Dysfunctional HDL correlates with the occurrence of coronary heart disease and peripheral arterial disease - Dysfunctional HDL is a prognostic marker of cardiovascular events (stroke, myocardial infarction, congestive heart failure hospitalization, death) in patients with subclinical or manifest atherosclerotic disease | — |
Secondary
| Measure | Time frame |
|---|---|
| - Identification of new mechanisms in the immunopathogenesis of arteriosclerosis - Dysfunctional HDL is a marker of endothelial dysfunction (measured by the FMD) | — |
Countries
Germany
Contacts
Public ContactNikolaos Pagonas
Klinik für Kardiologie und Angiologie, Klinikum Brandenburg, Medizinische Hochschule Brandenburg
Outcome results
None listed